https://www.pharmaradar360.com/article/676c9a07c4328c30Pharma Surgeen2026-05-11T10:02:32.000ZClass 4 Medicines Defect Notification: Milpharm Limited, Loperamide hydrochloride 2 mg Orodispersible Tablets, EL(26)A/23https://www.pharmaradar360.com/article/643615aec952345aPharma Surgeen2026-05-11T09:25:55.000ZPre market medical devices regulation – stakeholder impact surveyhttps://www.pharmaradar360.com/article/4d7b236f08cdc935Pharma Surgeen2026-05-11T08:00:03.000ZConsultation on the regulation of Gene therapy medicinal productshttps://www.pharmaradar360.com/article/b27c35f20bccd43dPharma Surgeen2026-05-11T07:26:55.000ZΓενόσημα Μαρτίου 2026_Τελικές Προτεινόμενες Τιμέςhttps://www.pharmaradar360.com/article/d88a8b30553b3461Pharma Surgeen2026-05-11T06:30:00.000Z中外製薬、独自の技術を活用した医薬品包装が世界包装機構の「WorldStar Global Packaging Awards 2026」において「WorldStar Winner 2026」を受賞https://www.pharmaradar360.com/article/5877ecc3f3b404f7Pharma Surgeen2026-05-11T06:30:00.000ZChugai’s Pharmaceutical Packaging Leveraging Proprietary Technologies Wins the “WorldStar Winner 2026” at the “WorldStar Global Packaging Awards 2026” from the World Packaging Organizationhttps://www.pharmaradar360.com/article/b7aaca31e3c5f13fPharma Surgeen2026-05-11T05:53:55.000ZTecovirimat SIGA (μονοϋδρική τεκοβιριμάτη): περιορισμός της ένδειξης λόγω έλλειψης αποτελεσματικότητας που καταδείχθηκε σε τυχαιοποιημένες κλινικές δοκιμές σε ασθενείς με mpoxhttps://www.pharmaradar360.com/article/fecbe8290d3cc797Pharma Surgeen2026-05-11T03:00:00.000Z[SHINSA]List of therapeutic products for which eligible patients can be identified by Drug-Agnostic CDx,postedhttps://www.pharmaradar360.com/article/5e0bed31a9834b2bPharma Surgeen2026-05-11T03:00:00.000Z[SHINSA]Software as a Medical Device (SaMD) page updatedhttps://www.pharmaradar360.com/article/b6dc004b26f208a6Pharma Surgeen2026-05-11T03:00:00.000Z[SHINSA]Points to Consider for Small Clinical Trials (Early Consideration) postedhttps://www.pharmaradar360.com/article/fb7a251ac3d5bbe5Pharma Surgeen2026-05-11T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/4c8729c2097d1b0bPharma Surgeen2026-05-11T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/d44668521e4b97aePharma Surgeen2026-05-11T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/1af26b04e46e7aabPharma Surgeen2026-05-11T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/df8fc13aeeb4582aPharma Surgeen2026-05-11T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/a6a8e4066350aa0ePharma Surgeen2026-05-11T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/1574e3e31048aeebPharma Surgeen2026-05-11T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/61a15df3f3987f25Pharma Surgeen2026-05-11T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/b8ea0b42c21c1098Pharma Surgeen2026-05-11T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/a88997d037145785Pharma Surgeen2026-05-11T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/dc9320471ce3e5c9Pharma Surgeen2026-05-11T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/08729da759487d8aPharma Surgeen2026-05-11T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/bb6350aea3537541Pharma Surgeen2026-05-11T00:00:00.000Z6203https://www.pharmaradar360.com/article/00a5059b3e25825bPharma Surgeen2026-05-11T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/8dd8dfad2666696aPharma Surgeen2026-05-11T00:00:00.000ZUnited Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026